{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', '7.4.', 'Pharmacodynamics (PD)', 'The PD markers (total IgG and IgG subtypes [IgG1, IgG2, IgG3 and IgG4], and', 'autoantibodies (anti-AChR antibodies for the AChR-Ab seropositive patients and anti-MuSK', 'antibodies for the MuSK-Ab seropositive patients) will be measured at the time points as', 'indicated in Table 1.', 'These PD markers will be determined using validated assays. The actual date and time of', 'collection of the blood sample will be recorded in the relevant section of the eCRF.', '7.5.', 'Anti-Drug Antibodies (ADA)', 'Blood samples to assess ADA will be collected pre-dose at the time points as indicated in', 'Table 1. At Baseline (SEB and TCnB), Screening, confirmatory and titer analysis will be', 'performed using a validated ADA assay. Samples having a positive ADA titer will be further', 'investigated in a neutralizing ADA assay. The actual date and time of collection of the blood', 'sample will be recorded in the relevant section of the eCRF.', '8.', 'STATISTICS', \"The statistical analyses will be performed by Sponsor's designated CRO using statistical\", 'analysis systems SAS (SAS Institute, Cary, NC, United States [US]) version 9.2 or higher,', 'and the software package R, if applicable. The standard operating procedures (SOPs) and', \"work instructions of Sponsor's designated CRO will be used as the default methodology if\", 'not otherwise specified.', 'Any change to the data analysis methods described underneath will be mentioned in the', 'statistical analysis plan (SAP). Any additional analysis, and the justification for making the', 'change, will be described in the clinical trial report (CTR). Additional exploratory analyses', 'of the data will be conducted as deemed appropriate.', '8.1.', 'Determinations of Sample Size', 'The null hypothesis HO states that there is no difference in proportion of MG-ADL', 'responders between patients treated with placebo and ARGX-113. The trial is powered at', '90% using significance level of 5% 2-sided to test the alternative hypothesis of that the', 'difference in the proportion of responders is 29% in favor of patients treated with', 'ARGX-113. The 29% is a weighted average of 80% AChR-Ab seropositive patients with', 'treatment difference of 35% and 20% AChR-Ab seronegative patients with treatment', 'difference of 5%. The proportion MG-ADL responders amongst patients treated with placebo', 'is hypothesized to be 30%. In order to test this alternative hypothesis, a sample size of', '150 patients is needed, with this allowing for 10% attrition rate.', 'argenx BVBA', 'Confidential', 'Page 87 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', '8.2.', 'Analysis Populations', 'The efficacy analyses will be done in the modified Intention-To-Treat (mITT: all randomized', 'patients who have a Baseline efficacy total score for MG-ADL and at least one post-Baseline', 'total MG-ADL score) and in the Per Protocol (PP) populations for sensitivity analyses of', 'primary and secondary endpoints. PP is defined as subset of mITT, i.e., all randomized', 'patients who have a Baseline efficacy total score for MG-ADL and at least one post-Baseline', 'total MG-ADL score and that received at least 3 out of 4 infusions (in any order), and', 'without a major protocol deviation. Safety analysis will be performed on safety set', 'comprising all patients in the randomized population who received at least one dose or part', 'of a dose. The safety analysis will be based on the actual treatment received.', '8.3.', 'Patient Disposition, Characteristics and Concomitant Medication', 'A tabular presentation of the patient disposition will be provided. It will include the number', 'of patients screened, randomized, completed, as well as the number of early discontinuations', 'from randomized treatment (including rescued patients) and trial, with reasons for', 'discontinuation from treatment or trial, and major protocol deviations.', 'A listing will be presented to describe dates of Screening, randomization or assigned', 'treatment, screen failure with reason, completion or early discontinuation and the reason for', 'discontinuation, if applicable, for each patient.', 'Patient characteristics will be recorded prior to randomization and will be listed and', 'summarized by treatment. Overall summaries will include descriptive statistics for', 'continuous measures (number of observations, mean, standard deviation, median, minimum', 'and maximum) and for categorical measures (frequency and percent). Patient characteristics', 'include, but are not limited to age, sex, race, weight, and body mass index (BMI).', 'Use of concomitant medication will be summarized by treatment with frequency and', 'percentage. All concomitant medications used will be listed.', '8.4.', 'Statistical Methods', '8.4.1.', 'Primary Endpoint Analyses', 'The primary endpoint is tested by means of a 2-sided exact test (using logistic regression)', 'stratified for the stratification factors Japanese VS non-Japanese patients, AChR-Ab serotype', 'and SoC at the 2-sided 5% significance level, in the AChR-Ab seropositive patients.', 'Percentage MG-ADL responders will be compared between ARGX-113 and placebo using', 'logistic regression model with Baseline total score as covariate and Japanese/non-Japanese', 'patient, AChR-Ab serotype and SoC as stratification variables.', 'argenx BVBA', 'Confidential', 'Page 88 of 110']\n\n###\n\n", "completion": "END"}